Global Asthma Drugs Market Report 2024, Forecast To 2033
8 Mar, 2024
The asthma drugs market has seen strong growth, rising from $23.05 billion in 2023 to $24.25 billion in 2024 at a CAGR of 5.2%. This growth is attributed to environmental factors and healthcare infrastructure development. The market is expected to continue growing, reaching $30 billion in 2028, with a CAGR of 5.5%. Factors contributing to this growth include rising air pollution levels and biopharmaceutical innovations. Major trends in the forecast period include personalized medicine and biomarker-guided therapies.
Global Asthma Drugs Market Key Driver
The high prevalence of asthmatic disorders, with asthma prevalence reaching 24.96 million in the US in 2021 according to the Centers for Disease Control and Prevention (CDC), is expected to propel the growth of the asthma drug market. The increasing number of asthmatic disorders drives the development of novel drugs to address the challenges posed by asthma, contributing to the growth of the asthma drug market.
Get A Free Sample Of The Global Asthma Drugs Market ReportGlobal Asthma Drugs Market Segments
The asthma drugs market covered in this report is segmented –
1) Type Of Asthma:Allergic, Non-Allergic
2) Asthma Trigger Type:Adult-Onset Asthma, Child-Onset Asthma, Cough-Induced Asthma, Exercise-Induced Asthma, Occupational Asthma, Nocturnal Asthma, Steroid-Resistant Asthma
3) Therapy:Preventive, Curative
4) Drug Class:Bronchodilators, Monoclonal Antibodies, Anti-Inflammatory Drugs, Combination Drugs
5) End-User:Asthma Patients, COPD Patients
By Geography: The countries covered in the asthma drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
North America was the largest region in the asthma drugs market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Major Asthma Drugs Industry Players
Pfizer Inc.; Roche Holding AG; Merck & Co. Inc.; Bayer AG; Sanofi S.A.; AstraZeneca PLC.; GlaxoSmithKline PLC.; Boehringer Ingelheim International GmbH; Teva Pharmaceutical Industries Ltd.; Novartis International AG; Mylan N.V.; Koninklijke Philips N.V; Cipla Limited; Chiesi Farmaceutici S.p.A.; Sun Pharmaceutical Industries Limited; Hikma Pharmaceuticals; Mundipharma International Limited; Lupin Limited; Glenmark Pharmaceuticals Limited; Hetero Drugs Limited; Alembic Pharmaceuticals Limited; Sunovion Pharmaceuticals Inc.; Amphastar Pharmaceuticals Inc.; Beximco Pharmaceuticals Ltd; Innoviva Inc.; Vectura Group; Circassia Group PLC; Pari Medical Holding GmbH; Pulmatrix Inc.; Atopix Therapeutics Limited
Get The Full Global Asthma Drugs Market Report
Asthma Drugs Market Overview
Asthma refers to a chronic lung disease that is caused by the inflammation and tightening of muscles around the airways, which makes patients suffer from effective breathing. This is caused when the airways get narrow, swollen, and blocked by excess mucus. Asthma drugs play a crucial role in managing asthma.